OXFORD, England & BOSTON – (COMMERCIAL THREAD(SAB) with the appointment of four distinguished leaders in the fields of neurodegeneration, rare genetic diseases and protein sciences. Dr Michael Schlossmacher, Professor Susan Perlman, Professor Ed Tate and Professor Christian Behl will help the company advance several series of new compounds in the development of Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and certain rare genetic diseases.
New SAB Members Will Join Guido Kroemer MD, PhD, Scientific Co-Founder of Samsara Therapeutics, a widely cited and renowned leader in cell biology and the autophagy process.
Michael Schlossmacher MD is professor of neurology at the University of Ottawa in Canada. After his medical training in Vienna and postgraduate studies in Alzheimer’s disease at Harvard University, he continued clinical training at Brigham & Women’s Hospital and Massachusetts General Hospital in Boston. Since 2000, he has focused his research activities on Parkinson’s disease, first at the Center for Neurologic Diseases at Brigham & Women’s Hospital and at Harvard Medical School. Since 2006, he has been based at the University of Ottawa, where he co-directs the Parkinson’s Research Consortium. In 2012, he was appointed holder of the Bhargava Research Chair in Neurodegeneration at the Ottawa Hospital Research Institute; in 2015, he was appointed director of his neuroscience program.
Susan Perlman MD, PhD is a Clinical Professor in the Department of Neurology at the David Geffen School of Medicine at UCLA and Director of the Ataxia and Neurogenetics Clinical Trials Programs. Professor Perlman is a well-known neuro-geneticist and clinical pioneer in ataxia who sits on the Medical Research Advisory Board of the National Ataxia Foundation. Perlman received his BS in Biochemistry from Cornell University and MD from SUNY, Stony Brook. She did her residency in neurology at UCLA, followed by a Muscular Dystrophy Association fellowship in neurology also at UCLA. In 2008, she received the Sherman M Mellinkoff Faculty Award, considered the highest faculty honor at the David Geffen School of Medicine.
Ed Tate PhD is Professor of Chemical Biology at Imperial College London and Satellite Group Leader at the Francis Crick Institute. Professor Tate is a leader in chemical biology and target identification techniques, and his group has made numerous contributions to the understanding of molecular interactions. After his doctorate at the University of Cambridge, he worked at the Ãcole Polytechnique and the Institut Pasteur (Paris), before joining Imperial College London where he was appointed professor of chemical biology in 2014. He has received numerous awards, the most recent of which is the RSC Corday 2020. Morgan Prize and Sir David Cooksey Translation Prize 2019, and serves on the editorial advisory boards of several prestigious chemical biology journals. He is a fellow of the Royal Societies of Chemistry and Biology and Director of the Imperial Center for Drug Discovery Science.
Christian Behl PhD received his doctorate in neurobiology from the Julius Maximilians University in WÃ¼rzburg. After postdoctoral research at the Salk Institute for Biological Studies in La Jolla and the Max Planck Institute of Psychiatry in Munich, he became Head of the Department of Pathobiochemistry at the Johannes Gutenberg University (JGU) in Mainz. He chaired the Institute of Physiological Chemistry and Pathobiochemistry and the Center for Interdisciplinary Research in Neurosciences (IFZN). Since 2010 he has been Director of the Institute of Pathobiochemistry of the University Medical Center (JGU) Mainz. Among other honors, he received the Binder Innovation Award from the German Society for Cell Biology (DGZ). Prof. Behl’s research interests focus on the study of cell aging, neurodegeneration, protein homeostasis and autophagy.
Jens Eckstein PhD, President of Samsara Therapeutics and Managing Partner, Apollo Health Ventures, commented: âBringing together this distinguished group of key opinion leaders will enable Samsara to develop its clinical strategy for an emerging pipeline of new therapies in currently incurable diseases. Their expertise and knowledge in the field of neurodegeneration, rare genetic diseases and protein science will be essential in stimulating the development of pioneer compounds to target key disease areas. “
Peter Hamley PhD, MBA, Scientific Director of Samsara Therapeutics, said: âWe look forward to working closely with the talented members of our new SAB to drive the clinical development of our promising pipeline while ensuring we build on the early successes of our technology platform. With this exceptional team of experts, we will continue to advance the discovery of neurodegeneration and therapies for rare genetic diseases. “
For more information on the Samsara SAB, please visit: www.samsaratherapeutics.com